C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
20 November 2023 - 11:00PM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science to develop a new generation of small-molecule
medicines and transform how disease is treated, today announced the
appointment of Owen Hughes to its board of directors. Mr. Hughes is
an accomplished life sciences executive with nearly three decades
of experience in investing, operations and corporate governance.
“We are thrilled to welcome Owen to the board of directors and
leverage his experience across capital markets and pivotal business
development opportunities,” said Bruce Downey, chairman of the
board of directors of C4 Therapeutics. “His knowledge will help C4
Therapeutics strategically advance our portfolio of novel degrader
medicines that have the potential to transform how disease is
treated.”
Mr. Hughes most recently served as co-founder and chief
executive officer of Cullinan Oncology, where he led the
development of the company’s portfolio of oncology assets through
proof-of-concept. Under Mr. Hughes’s leadership, Cullinan raised
over $400 million in capital through its initial public offering
and advanced several assets into the clinic. Mr. Hughes also served
as chief business officer of Intarcia Therapeutics, where he raised
over $1.4 billion in capital and completed several portfolio deals
totaling more than $1 billion.
Mr. Hughes started his career on Wall Street, initially in
investment banking and equity research before transitioning to the
buyside, where he managed public and private healthcare investments
for Brookside Capital, a hedge fund under the Bain Capital
umbrella, and Pyramis Advisors, a Fidelity Investments company.
Mr. Hughes currently serves as the executive chairman of Sail
Bio and XOMA Corporation as well as the chairman of Ikena Oncology.
He previously served on the boards of Radius Health (acquired by
Gurnet Point Capital) and Translate Bio (acquired by Sanofi). Mr.
Hughes earned a B.A. in history from Dartmouth College.
“It is a privilege to join C4T’s board and help advance targeted
protein degradation in hopes it may offer patients and physicians a
new therapeutic option,” said Mr. Hughes. “I look forward to
working with the board of directors and management team to
capitalize on the company’s scientific prowess to the benefit of
patients and shareholders alike.”
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is leveraging its TORPEDO® platform
to efficiently design and optimize small-molecule medicines that
harness the body’s natural protein recycling system to rapidly
degrade disease-causing proteins, offering the potential to
overcome drug resistance, drug undruggable targets and improve
patient outcomes. C4T is advancing multiple targeted oncology
programs to the clinic and expanding its research platform to
deliver the next wave of medicines for difficult-to-treat diseases.
For more information, please visit www.c4therapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of C4
Therapeutics, Inc. within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements may
include, but may not be limited to, express or implied statements
regarding our ability to develop potential therapies for patients;
the design and potential efficacy of our therapeutic approaches;
the potential timing, design and advancement of our preclinical
studies and clinical trials, including the potential timing for and
receipt of regulatory authorization related to clinical trials and
other clinical development activities including clinical trial
commencement; and our ability to fund our future operations. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: uncertainties
related to the initiation, timing, advancement and conduct of
preclinical and clinical studies and other development requirements
for our product candidates; the risk that any one or more of our
product candidates will cost more to develop or may not be
successfully developed and commercialized; and the risk that
sufficient capital to fund our future operations will be available
to us on acceptable terms or at the times required. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in C4 Therapeutics’ most recent
Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as
filed with the Securities and Exchange Commission. All information
in this press release is as of the date of the release, and C4
Therapeutics undertakes no duty to update this information unless
required by law.
Contacts:Investors: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate
Communications & Patient
Advocacy LSpreen@c4therapeutics.com
C4 Therapeutics (NASDAQ:CCCC)
Historical Stock Chart
From Apr 2024 to May 2024
C4 Therapeutics (NASDAQ:CCCC)
Historical Stock Chart
From May 2023 to May 2024